Comparative Pharmacology
Head-to-head clinical analysis: NEURAMATE versus NEURONTIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NEURAMATE versus NEURONTIN.
NEURAMATE vs NEURONTIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
NEURAMATE is a brand name for pentobarbital, a barbiturate that enhances GABA-A receptor activity by binding to the barbiturate binding site, increasing the duration of chloride ion channel opening, thereby producing CNS depression.
Gabapentin binds to the α2δ subunit of voltage-gated calcium channels, inhibiting calcium influx and reducing neurotransmitter release, particularly glutamate, norepinephrine, and substance P. It does not interact with GABA receptors.
250 mg orally three times daily; maximum 1000 mg/day.
300 mg orally once daily on day 1, 300 mg twice daily on day 2, then 300 mg three times daily on day 3; titrate up to effective dose, usual maintenance 300-600 mg three times daily, maximum 3600 mg/day.
None Documented
None Documented
6-8 hours (normal renal function); prolonged to 12-20 hours in moderate renal impairment.
Terminal elimination half-life is 5–7 hours in patients with normal renal function; in elderly or those with renal impairment, half-life may be prolonged up to 132 hours; requires dose adjustment for creatinine clearance <60 mL/min.
Primarily renal (90% unchanged) with 10% biliary/fecal.
Renal elimination as unchanged drug: >90%; 0.3% is excreted in feces; biliary elimination is negligible.
Category C
Category C
Antiepileptic
Antiepileptic